JP2018502137A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502137A5
JP2018502137A5 JP2017537924A JP2017537924A JP2018502137A5 JP 2018502137 A5 JP2018502137 A5 JP 2018502137A5 JP 2017537924 A JP2017537924 A JP 2017537924A JP 2017537924 A JP2017537924 A JP 2017537924A JP 2018502137 A5 JP2018502137 A5 JP 2018502137A5
Authority
JP
Japan
Prior art keywords
halo
pharmaceutically acceptable
independently selected
group
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2017537924A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502137A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/013507 external-priority patent/WO2016118403A1/en
Publication of JP2018502137A publication Critical patent/JP2018502137A/ja
Publication of JP2018502137A5 publication Critical patent/JP2018502137A5/ja
Ceased legal-status Critical Current

Links

JP2017537924A 2015-01-20 2016-01-15 第XIa因子阻害剤 Ceased JP2018502137A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105385P 2015-01-20 2015-01-20
US62/105,385 2015-01-20
PCT/US2016/013507 WO2016118403A1 (en) 2015-01-20 2016-01-15 Factor xia inhibitors

Publications (2)

Publication Number Publication Date
JP2018502137A JP2018502137A (ja) 2018-01-25
JP2018502137A5 true JP2018502137A5 (enExample) 2019-02-21

Family

ID=56417605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017537924A Ceased JP2018502137A (ja) 2015-01-20 2016-01-15 第XIa因子阻害剤

Country Status (11)

Country Link
US (1) US10123995B2 (enExample)
EP (1) EP3247354B1 (enExample)
JP (1) JP2018502137A (enExample)
KR (1) KR20170103962A (enExample)
CN (1) CN107106548A (enExample)
AU (1) AU2016209623B2 (enExample)
BR (1) BR112017015431A2 (enExample)
CA (1) CA2973202A1 (enExample)
MX (1) MX2017009445A (enExample)
RU (1) RU2712268C2 (enExample)
WO (1) WO2016118403A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9975874B2 (en) 2014-07-28 2018-05-22 Merck Sharp & Dohme Corp. Factor XIa inhibitors
US10081617B2 (en) 2015-04-16 2018-09-25 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3383847B1 (en) * 2015-12-02 2022-08-24 Merck Sharp & Dohme LLC FACTOR XIa INHIBITORS
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
EP3351122B1 (en) * 2016-10-12 2020-06-17 Changzhou Patent Electronic Technology Co., Ltd Mouth piece of electronic cigarette, e-liquid cartridge, and electronic cigarette
WO2021121396A1 (zh) * 2019-12-20 2021-06-24 成都康弘药业集团股份有限公司 作为血浆激肽释放酶抑制剂的三环类化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163749B2 (en) * 2005-12-14 2012-04-24 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007109459A2 (en) * 2006-03-21 2007-09-27 Janssen Pharmaceutica, Nv Pyridines and pyridine n-oxides as modulators of thrombin
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
KR101843542B1 (ko) * 2010-02-11 2018-03-30 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 마크로사이클
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
EP2744499B1 (en) 2011-08-19 2016-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2015111206A (ru) 2012-08-30 2016-10-20 Ниппон Синяку Ко., Лтд. Пиридиновое производное и лекарственное средство
WO2014081618A1 (en) * 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Thrombin inhibitors
CN106413710A (zh) 2014-05-28 2017-02-15 默沙东公司 因子XIa抑制剂
WO2016018701A1 (en) 2014-07-28 2016-02-04 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
EP3180317B1 (en) 2014-07-28 2021-04-14 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
US9975874B2 (en) 2014-07-28 2018-05-22 Merck Sharp & Dohme Corp. Factor XIa inhibitors

Similar Documents

Publication Publication Date Title
JP2017517512A5 (enExample)
JP2018502137A5 (enExample)
RU2016150410A (ru) Ингибиторы фактора xia
JP2016530259A5 (enExample)
JP2016515560A5 (enExample)
JP2018531954A5 (enExample)
JP2017504640A5 (enExample)
JP2013537203A5 (enExample)
JP2016515561A5 (enExample)
JP2016540742A5 (enExample)
JP2015520769A5 (enExample)
RU2017129275A (ru) ИНГИБИТОРЫ ФАКТОРА XIa
JP2013523763A5 (enExample)
JP2016531126A5 (enExample)
JP2014508811A5 (enExample)
JP2016517417A5 (enExample)
JP2015501833A5 (enExample)
JP2017523169A5 (enExample)
RU2018119015A (ru) ИНГИБИТОРЫ ФАКТОРА XIa
JP2019505529A5 (enExample)
RU2017124150A (ru) Производное дигидроиндолизинона
EA201391558A1 (ru) Тетрагидропиразоло[1,5-а]пиримидины как противотуберкулезные соединения
JP2016528273A5 (enExample)
JP2015521195A5 (enExample)
AR098522A1 (es) Compuesto de triazolo-piridina